Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Heres whats known so far, what remains uncertain, and what you should ask your healthcare professionals
Spontaneous post-marketing reports occasionally mention sleep difficulties in people taking semaglutide or other GLP-1 receptor agonists, though these reports remain anecdotal rather than systematically documented
Developer: Eli Lilly and Company | Administration in Trials: Once-weekly subcutaneous injection First successful Phase 3 trial (TRIUMPH-4, topline Dec 2025): Up to 28.7% average body weight loss at 68 weeks (highest dose) in adults with obesity/overweight and knee osteoarthritis
Hims & Hers has been slowly expanding its global reach and recently acquired the European telehealth platform ZAVA
This combination can lead to significant weight loss and better diabetes management
